High PFS” or “
Low PFS”.
Models accurately predicted PFS status for several cancer types, including adrenocortical carcinoma, glioma, mesothelioma, and sarcoma.
In conclusion, the P142 panel of metrics successfully predicted cancer progression status in patients with some, but not all cancer types analyzed.
The P142 panel of metrics successfully predicted cancer progression status in patients with some, but not all cancer types analyzed.
Cancer is a leading cause of human mortality worldwide and the incidence of cancer is expected to rise as our average life expectancy increases.
Furthermore, the accumulation of specific deaminase-associated mutations in a patient can provide valuable information on how the cancer has developed, and in specific cases provide information on the rate of progression of the disease and likely response to specific treatments.
Mutation-signature–associated metrics predict cancer progression in patients
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Scandion Oncology reports positive interim results from the CORIST Phase II study
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
Switzer Daily
19 May 2021
The IIR Pharma & Biotech Index performed well in April, up 6.2% Month-on-Month (MoM). This was above the ASX All Ordinaries Accumulation Index and the ASX Small Ordinaries Accumulation Index which were up 3.9% and 5.0% MoM, respectively.
Of the 140 companies in the IIR Pharma & Biotech Index, only 38 companies have a negative share price return over the 12-months to 30 April 2021 and 48 companies have a share price return of 100% or more.
ADO makes top 10
Anteotech Ltd (ASX: ADO) made its way into the top 10 constituents in April after the share price increased 74% for the month. The market cap of ADO has increased from $37.8 m to $815.3 m over the 12-months to April-end. We note that post month-end, the share price has weakened on the back of a capital raising at a significant discount.